Polaris: China Deal Monitor: Delian Capital backs Polaris and more updates
Oncology-focused medical technology company Shanghai Polaris Biology Co., Ltd has garnered 70 million yuan ($9.9 million) in a Series B round of financing led by new backer Delian Capital, per a company announcement.
Read full article »
CEO
Polaris is a biotechnology company that develops and commercializes novel diagnosis therapies for the treatment of cancer.
Read more